Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study

Martin Wasserbauer¹, Stepan Hlava¹*, Milan Trojanek², Jan Stovicek¹, Tomas Milota³, Jiri Drabek¹, Petra Koptová¹, Andrea Cupkova¹, Dita Pichlerová¹, Barbora Kucerova⁴, Stepan Coufal⁵, Radan Keil¹

¹ Department of Internal Medicine, 2nd Faculty of Medicine Charles University in Prague and Motol University Hospital, Prague, Czech Republic, 2 1st Department of Infectious Diseases, 2nd Medical Faculty Charles University in Prague and Hospital Na Bulovce, Prague, Czech Republic, 3 Department of Immunology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic, 4 Department of Pediatric Surgery, 2nd Faculty of Medicine Charles University in Prague and University Hospital Motol, Prague, Czech Republic, 5 Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic

* stepan.hlava@fnmotol.cz

Abstract

Background and aims
SARS-CoV-2 is a worldwide serious health problem and vaccination seems to have a crucial role in managing the COVID-19 pandemic. The aim of this prospective observational study was to monitor the trend of antibodies against SARS-CoV-2 after vaccination with BNT162b2 (COMIRNATY) in patients with inflammatory bowel disease treated by immunosuppressive and/or biological therapy, demonstrate whether any type of this therapy is associated with poorer production of antibodies against COVID-19 and evaluate the safety of vaccination against COVID-19 in these patients.

Methods
Eighty-seven eligible patients from one tertiary gastroenterological center with inflammatory bowel disease (60 with CD, 27 with UC) treated by immunosuppressive and/or biological therapy from the antiTNFα group were indicated to vaccination against SARS-CoV-2. Effectiveness of vaccination was evaluated by the values of antibodies before and 4 weeks after 2nd dose of vaccine. Additional goal was to evaluate adverse events of vaccination.

Results
Before the 2nd dose of vaccine, geometric mean of SARS-CoV-2 IgG antibodies were 40.7 U/ml in the biological therapy group, 34.8 U/ml in the azathioprine group and 44.8 U/ml in the combination therapy group of patients. The geometric means were 676.5.7 U/ml in the biological therapy group, 614.4 U/ml in the azathioprine group and 500.1 U/ml in the
combination therapy group of patients four weeks after 2\textsuperscript{nd} dose. Statistically significant differences between these groups were not proved. Several non-severe local and general adverse events were present in our patients with a majority of these events on the day of vaccine administration and the day after, no anaphylactic reactions were present.

Conclusions
Our measurements proved the efficacy and safety of vaccination against SARS-CoV-2 in patients with inflammatory bowel disease treated by immunosuppressive and/or biological therapy. Statistically significant differences between our groups of patients were not proved.

Introduction
At the end of 2019 a new coronavirus appeared (then called SARS-CoV-2) which rapidly resulted in a pandemic with serious health and also economic consequences. Infection of SARS-CoV-2 is characterized by rapid transmission of the virus between people [1, 2]. A dysregulated immune response followed by a cytokine storm plays a crucial role in the pathogenesis of COVID-19 infection [3]. Especially in high-risk groups of patients, infection may result in acute respiratory distress syndrome, multiorgan failure and death. Mortality of COVID-19 infection is high and especially elderly patients and patients with comorbidities are at increased risk of death [4].

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic inflammatory disorder of the gastrointestinal tract. The management of IBD typically requires lifelong pharmacological therapy, often including during the past decade immunosuppressive or biological therapy, to induce and maintain remission [5, 6]. Immunosuppressive and biological therapy (especially in combination) is associated with higher risk of viral, bacterial, parasitic or fungal opportunistic infection [7, 8]. Each of these immunomodulators can lead to several type of opportunistic infection despite different mechanisms of action. To this date, few data about COVID-19 infection in patients with IBD has been published. Available but limited data suggest that patients with IBD are not at a higher risk of COVID-19 infection than the general population and immunosuppressive or biological therapy is not associated with a higher mortality rate [9–11].

Direct antiviral treatment for COVID-19 infection is not available as of the date of publication, and therapy for COVID-19 infection is predominantly symptomatic. During the COVID-19 pandemic, countries have focused mainly on preventive methods, namely non-specific (patient triage, social distancing, personal hygiene and disinfection and use of personal protective equipment) and specific (vaccination) ones. Vaccines against COVID-19 infection are available in several different platforms [12] and nowadays widely used. Patients with IBD are also indicated for vaccination against COVID-19 infection to reduce the incidence of infection in this population group and to minimize the acute and chronic consequences of this infection.

The aim of this observational prospective study was to monitor the trend of development of antibodies against COVID-19 after vaccination in patients with IBD, who are being treated by immunosuppressive and/or biological therapy from the group of Tumor necrosis factor \(\alpha\) inhibitors (antiTNF\(\alpha\)), and demonstrate whether any type of chronic immunosuppressive/biological therapy for IBD was associated with poorer production of antibodies against COVID-19. The second goal of the study was to evaluate the safety of vaccination against COVID-19.
Materials and methods

Patients

A prospective observational study was performed at the Gastroenterology Department in Motol University Hospital in Prague, Czech Republic in outpatients > 18 years of age. Patients with CD or UC were eligible to participate in the study if they used a medication containing immunosuppressive therapy (azathioprine) and/or biological therapy from the antiTNFα group (infliximab, adalimumab, golimumab) and were indicated to vaccination against SARS-CoV-2. In order to ensure that results were not affected by potentially confounding factors, exclusion criteria were as follows: chronic or recent (≤ 2 weeks before vaccination) use of corticosteroids and infection of COVID-19 before vaccination. During the study, patients received the usual care from their gastroenterologists, which was not modified because of the study.

Ethical statement

The study protocol was approved by the ethics committee of the Second Faculty of Medicine, Charles University in Prague, Czech Republic. All participants of our study (patients over 18 years of age) signed an informed consent.

Methods

Eligible patients (men and women) with CD or UC were indicated to vaccination against SARS-CoV-2 with BNT162b2 (COMIRNATY, Pfizer-BioNTech) COVID-19 vaccine according to the indication criteria listed in the Summary of Product Characteristics in the Czech Republic. No patient selection for vaccination or inclusion into our study was done. All patients of our gastroenterological center were gradually vaccinated. All patients treated by immunosuppressive (azathioprine) and/or biological therapy (antiTNFα group), who agreed to participate with our study, were included. Patients received two doses of the vaccine about 3 weeks apart. Patients agreed to the vaccination and confirmed their consent by signing an informed consent.

Information about patients was collected at the beginning of the monitoring in order to collect information on baseline demographics and characteristics. In patients enrolled in the study, serum levels of COVID-19 antibodies in the IgG classes were collected three times during the entire follow-up: at baseline before the 1st dose of vaccine, before the 2nd dose of vaccine (approximately 3 weeks after the 1st dose) and 4 weeks after the 2nd dose of the vaccine. Based on the value of antibodies against SARS-CoV-2 before the 2nd dose of vaccine and 4 weeks after the 2nd dose of the vaccine, patients were divided into 3 groups: non-responders (SARS-CoV-2 antibodies IgG less than 100 U/ml), partial responders (SARS-CoV-2 antibodies IgG less than 100 U/ml and more), and responders SARS-CoV-2 antibodies IgG 500 U/ml and more).

An immune-enzymatic kit (EIA COVID-19 RBD IgG CoRG96) was used for laboratory analysis to determine IgG antibodies against the receptor-binding domain (RBD) of SARS-CoV-2 virus in human serum. RBD is a key part of SARS-CoV-2 virus. RBD, a subunit of the spike S1 protein, binds specifically to the angiotensin-converting enzyme 2 of the host cell and allows virus to entry into cells, which could lead to infection. This binding is highly correlated with the formation of neutralizing antibodies. This kit allows the detection of specific IgG class antibodies in a serum sample by enzyme immunoassay. The labeled antibody is a peroxidase-conjugated animal immunoglobulin fraction against human IgG. Peroxidase activity is determined using a substrate with tetramethylbenzidine, which turns blue in case of positivity. The whole reaction is stopped with a stop solution. The blue color changes to yellow. The intensity
of the yellow color is measured on a photometer (at a wavelength of 450 nm) and is proportional to the concentration of specific IgG antibodies present in the sample. In our measurements, the concentration of IgG against SARS-CoV-2 was measured up to the maximum limit of 1000 U/ml, higher concentrations were no longer measured.

Questionnaires focused on the safety of the administered vaccine (S1 Fig) were anonymously distributed to randomly selected patients from the study group. This questionnaire was created by our group, focused directly on the parameters under our consideration and intention. Questionnaires were completed on the day of vaccine administration and for the following 7 days—after the 1\textsuperscript{st} and also after the 2\textsuperscript{nd} dose of vaccine (a total of 16 days, 8 days after both doses). The questionnaires were designed the same for each day. This questionnaire consisted of 3 parts, which measured three forms of side effects of the SARS-CoV-2 vaccine: local reactions (pain and erythema at the injection site), general symptoms (body temperature, headache, arthralgia, myalgia, fatigue and others) and general well-being (on a scale from 0–100).

The primary outcome of the study was to monitor the development of antibodies against SARS-CoV-2 after vaccination in patients with IBD, who were treated by immunosuppressive and/or biological therapy from the antiTNF\(\alpha\) group, and demonstrate whether any type of chronic immunosuppressive/biological therapy for IBD was associated with poorer production of antibodies against SARS-CoV-2. The secondary outcome of the study was to evaluate the safety of vaccination against SARS-CoV-2. This study was designed as prospective observational study.

**Statistical analysis**

Stata 14 software (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP) was used for statistical analysis. A censored linear regression model with random effects was used for data comparing IgG antibody levels and applied to logarithmic IgG data (distribution of measured values is asymmetric). Censored regression can work with data with incomplete information, i.e, with the indication that the observation is above a certain limit (here, for example, IgG > 1000 U/ml). The model also takes into account, through random effects, that these are repeated observations on the same individuals. Fisher’s exact test was used to determine whether there is any difference in proportions between groups.

**Results**

**Patient demographics and disposition**

Eighty-seven eligible patients (52 men and 35 women) who had been diagnosed with IBD (60 with CD, 27 with UC) were enrolled (Table 1). Between UC and CD, there were no statistically significant differences in sex representation (p = 0.480), age (p = 0.244) or therapy types.

|                   | N (%)       | Crohn’s disease N (%) | Ulcerative colitis N (%) |
|-------------------|-------------|-----------------------|-------------------------|
| **Sex**           |             |                       |                         |
| Men               | 52 (59.8)   | 34 (56.7)             | 18 (66.7)               |
| Women             | 35 (40.2)   | 26 (43.3)             | 9 (33.3)                |
| **IBD therapy**   |             |                       |                         |
| Biological therapy| 47 (54.0)   | 36 (60.0)             | 11 (40.7)               |
| Azathioprine      | 28 (32.2)   | 17 (28.3)             | 11 (40.7)               |
| Biological therapy and azathioprine | 12 (13.8) | 7 (11.7) | 5 (18.5) |
| **Total**         | 87          | 60                    | 27                      |

https://doi.org/10.1371/journal.pone.0273612.t001
Patients were between 23 and 74 years of age, and the median of age was 50. Patients were divided into three groups according to their therapy: biological therapy from the antiTNFα group only (47 patients—36 with CD and 11 with UC), immunosuppressive therapy with azathioprine only (28 patients—17 with CD and 11 with UC) and a combination of biological therapy from the antiTNFα group and azathioprine group (12 patients—7 with CD and 5 with UC). In the group of patients with biological therapy, 25 patients were treated with infliximab, 21 patients with adalimumab and 1 patient with golimumab. A total of 35 patients were treated with biological therapy in a classic dosing schedule and 12 patients were treated in an intensified regimen (higher dose or shortened interval). In the group of patients with a combination of biological therapy from the antiTNFα group and azathioprine group, 7 patients were treated with infliximab, 5 patients with adalimumab and no patients with golimumab. In the group of patients who were using azathioprine, the median dosage per day was 1.4 mg/kg in the range of 0.3–2.8 mg/kg. Finally, the median interval between vaccine doses was 23 days, ranging from 21 to 25 days.

**Measure of antibodies against SARS-CoV-2**

IgG antibodies against SARS-CoV-2 were measured according to our protocol in all 3 groups of patients, geometric means (standard errors) (Fig 1) (Table 2):

1. **Group of patients treated with biological therapy (n = 47).** All patients had negative values of antibodies IgG against SARS-CoV-2 before the 1st dose of vaccine against SARS-CoV-2—geometric mean of values of antibodies IgG against SARS-CoV-2 was 0.4 U/ml (0.1). Three weeks after 1st dose (before 2nd dose) geometric mean of values of antibodies IgG against SARS-CoV-2 was 40.7 U/ml (13.0). Four weeks after 2nd dose geometric mean was 676.5 U/ml (142.8).

2. **Group of patients treated with azathioprine (n = 28).** All patients had negative values of antibodies IgG against SARS-CoV-2 before the 1st dose of vaccine against SARS-CoV-2—
geometric mean of values of antibodies IgG against SARS-CoV-2 was 0.4 U/ml (0.1). Median and geometric mean of values of antibodies IgG against SARS-CoV-2 three weeks after 1st dose was 34.9 U/ml (13.0). Four weeks after 2nd dose geometric mean was 614.4 U/ml (168.1).

3. Group of patients treated with the combination of biological therapy and azathioprine (n = 12). All patients had negative values of antibodies IgG against SARS-CoV-2 before the 1st dose of vaccine against SARS-CoV-2 – geometric mean of values of antibodies IgG against SARS-CoV-2 was 0.5 U/ml (0.2). Three weeks after 1st dose geometric mean of values of antibodies IgG against SARS-CoV-2 was 44.8 U/ml (29.0). Four weeks after 2nd dose geometric mean was 500.1 U/ml (209.1).

Statistically significant increases in the geometric means of values of antibodies IgG against SARS-CoV-2 in all three studied groups of patients (biological therapy only, azathioprine only and combination therapy) were proved before the 1st dose vs. three weeks after 1st dose (before 2nd dose) (p < 0.001) and three weeks after 1st dose vs. one month after 2nd dose (p < 0.001). The evaluation within IBD diagnoses is described in Table 2.

Comparison of effectiveness of vaccination against SARS-CoV-2 between monitored groups of patients

Comparison of geometric means in the trend between two time periods and two selected groups:

1. Biological therapy group vs. group of patients with azathioprine—statistically significant differences in antibodies IgG trends were not proved before 1st and 2nd doses (p = 0.470) and nor before 2nd and one month after 2nd dose (p = 0.450).

2. Biological therapy group vs. group of patients with a combination of biological therapy and azathioprine—statistically significant differences in antibodies IgG trends were not proved before 1st and 2nd doses (p = 0.810) and nor before 2nd and one month after 2nd dose (p = 0.710).
3. Combination of biological therapy and azathioprine group vs. group of patients with only azathioprine—statistically significant differences in antibodies IgG trends were not proved before 1st and 2nd doses (p = 0.780) and nor before 2nd and one month after 2nd dose (p = 0.380).

Statistically significant differences in the values of antibodies against SARS-CoV-2 between our groups of patients (biological therapy only, azathioprine only and combination therapy) were not proved.

Effectiveness of vaccination against SARS-CoV-2

Based on the value of antibodies against SARS-CoV-2, patients were divided into responders, partial responders and non-responders (Fig 2):

1. In the group of patients treated with biological therapy (n = 47, 36 with CD and 11 with UC), only 13 patients (27.7%)(8 with CD and 5 with UC) were responders to vaccination already after the 1st dose, 4 patients (8.5%)(all with CD) were partial responders and 30 patients (63.8%)(24 with CD and 6 with UC) were non-responders. A total of 41 patients (87.2%)(30 with CD and 11 with UC) were responders to vaccination after the 2nd dose, 4 patients (8.5%)(all with CD) were partial responders and 2 patients (4.3%)(all with CD) were non-responders four weeks after the 2nd dose of vaccine against COVID-19.

2. In the group of patients treated with azathioprine (n = 28, 17 with CD and 11 with UC), only 3 patients (10.7%)(2 with CD and 1 with UC) were responders to vaccination already after the 1st dose, 4 patients (14.3%)(2 with CD and 2 with UC) were partial responders and 21 patients (75.0%)(13 with CD and 8 with UC) were non-responders. A total of 24 patients (85.7%)(14 with CD and 10 with UC) were responders to vaccination after the 2nd dose, 1 patient (3.6%)(with UC) was a partial responder and 3 patients (10.7%)(all with CD) were non-responders four weeks after the 2nd dose of vaccine against COVID-19.

![Fig 2. Comparison of responders, partial responders and non-responders between all 3 groups of patients based on the value of antibodies against SARS-CoV-2.](https://doi.org/10.1371/journal.pone.0273612.g002)
3. In the group of patients treated with a combination of biological therapy and azathioprine (n = 12, 7 with CD and 5 with UC), 3 patients (25.0%) (1 with CD and 2 with UC) were responders to vaccination already after the 1st dose, 1 patient (8.3%) (with CD) was a partial responder and 8 patients (66.7%) (5 with CD and 3 with UC) were non-responders. A total of 9 patients (75.0%) (5 with CD and 4 with UC) were responders to vaccination after the 2nd dose, 1 patient (8.3%) (with CD) was a partial responder and 2 patients (16.7%) (1 with CD and 1 with UC) were non-responders four weeks after the 2nd dose of vaccine against COVID-19.

Patients treated only by azathioprine (n = 28) were also divided into 2 groups based on the dose of azathioprine. A total of 6 patients had a dose of azathioprine of 2mg/kg/day and more, of which 1 patient (16.7%) was a non-responder after the 2nd dose of vaccine and 5 patients (83.3%) were responders or partial responders. In the group of 22 patients with azathioprine dose below 2mg/kg/day, 2 patients (9.1%) were non-responders and 20 patients (90.9%) were responders or partial responders 4 weeks after the 2nd dose of vaccination. Statistically significant differences between these two groups of patients were not proved (p = 0.530).

Patients treated only by biological therapy (n = 47) were also divided into 2 groups based on a normal or intensified dosing regimen. A total of 12 patients had an intensified regimen of biological therapy, of which 1 patient (8.3%) was a non-responder after the 2nd dose of vaccination and 11 patients (91.7%) were responders or partial responders. In the group of 35 patients with a classic dosing schedule of biological therapy, 1 patient (2.9%) was a non-responder and 34 patients (97.1%) were responders or partial responders 4 weeks after the 2nd dose of vaccination. Statistically significant differences between these two groups of patients were not proved (p = 0.450).

Safety and tolerability of COVID-19 vaccine BNT162b2

A total of 49 questionnaires (32 patients with CD and 17 with UC) were evaluated in these three aspects of safety and tolerability of SARS-CoV-2 vaccine BNT162b2:

1. Local reactions (pain and/or erythema at the injection site):
   - Most local reactions were observed on the day of administration (day 0) and the following day (day 1) after the 1st and 2nd dose of vaccine. In the following days, there was a significant decrease in the incidence of local reactions (Fig 3). Erythema was observed on day 0 in 28 patients (57.2%) after the 1st and 2nd dose of vaccine (median of erythema severity was 3 and 2, respectively). On day 1, the progression of erythema frequency in the study group of patients after the 1st and 2nd dose of vaccine was observed in 37 (75.5%) and 32 patients (65.3%), respectively (median severity of erythema was 2 and 3, respectively). Local pain was observed on day 0 after the 1st and 2nd doses of vaccine in 2 patients (4.2%) and 1 patient (2.1%), respectively (median erythema severity was 3 and 2, respectively).

2. General symptoms (body temperature, headache, arthralgia, myalgia and others):
   - A majority of general reactions were observed on the day of administration (day 0) and the following day (day 1) after the 1st and 2nd dose of vaccine with significant decrease following in the days afterward (Fig 4). Mainly fever, myalgia, arthralgia, cephalgia and fatigue were observed during our monitoring after the first and second dose of vaccine (Table 3). Body temperature ≥ 37.0°C in evening was present after the 1st dose and after the 2nd dose of vaccine on day 0 in 5 (10.2%) and 6 (12.2%) patients, respectively; on day 1 in 2 (4.1%)
and 7 (14.3%) patients, respectively; on day 7 in 2 (4.1%) and 1 patient (2.0%), respectively. Myalgia was present after the 1st dose and after the 2nd dose of vaccine on day 0 in 7 (14.3%) and 5 (10.2%) patients, respectively; on day 1 in 6 (12.2%) and 13 (26.5%) patients, respectively; on day 7 in 0 (0.0%) and 2 patients (4.1%), respectively. Arthralgia was present after the 1st dose and after the 2nd dose of vaccine on day 0 in 6 (12.2%) and 5 (10.2%) patients, respectively; on day 1 in 5 (10.2%) and 13 (26.5%) patients, respectively; on day 7 in 0 (0.0%) and 2 patients (4.1%), respectively. Cephalgia was present after the 1st dose and
after the 2\textsuperscript{nd} dose of vaccine on day 0 in 10 (20.4\%) and 11 (22.4\%) patients, respectively; on day 1 in 13 (26.5\%) and 12 (24.5\%) patients, respectively; on day 7 in 0 (0.0\%) and 2 patients (4.1\%), respectively. Fatigue was present after the 1\textsuperscript{st} dose and after the 2\textsuperscript{nd} dose of vaccine on day 0 in 10 (20.4\%) and 12 (24.5\%) patients, respectively; on day 1 in 6 (12.2\%) and 10 (20.4\%) patients, respectively; on day 7 in 1 (2.1\%) and 4 patients (8.2\%), respectively. The other symptoms were: pruritic rash, nausea, vertigo, back pain, painful lymphadenopathy and dyssomnìa. These other symptoms were described only in individual patients and not in more than 2 patients from our observed spectrum (less than 5\% of patients). There was no reported severe allergic reaction in terms of anaphylaxis.

3. General well-being (in scale from 0–100):

- General well-being was monitored after the 1\textsuperscript{st} and 2\textsuperscript{nd} doses of vaccine (0 worst, 100 best). The first dose was better tolerated by patients than the 2\textsuperscript{nd} dose of vaccine (Fig 5).

![Fig 5. General well-being after SARS-CoV-2 vaccination—development in time.](https://doi.org/10.1371/journal.pone.0273612.g005)
Discussion

A wide spectrum of protective mechanisms has been implemented in the management of prevention of COVID-19 infection, but vaccination is considered to be the most promising tool for managing present pandemic and preventing future outbreaks of this disease [13]. During a relatively short period of time several vaccines became available for use in preventing especially severe forms of COVID-19 infection. Severe form of COVID-19 infection predominantly occurs in high-risk patients (advanced age, medical comorbidities and use of immunomodulatory therapy) [14–18]. Therefore, the issue of vaccination against SARS-CoV-2 in immunocompromised patients or in patients who are using immunomodulatory therapy, such as patients with IBD, is widely recommended with respect to the potential for severe COVID-19 infection. Generally, patients with IBD in remission are not at a higher risk for SARS-CoV-2 infection and these patients should continue their chronic therapy to sustain remission [19]. Risk factors for severe COVID-19 in IBD patients seems to be increasing age, more than 2 comorbidities, use of systemic glucocorticoids and mesalamine/sulfasalazine [11]. Biological therapy with anti-TNF agents is not associated with severe form of COVID-19 [11]. On the other hand, azathioprine, especially in combination with anti-TNF biological therapy, seems to be associated with increased risk of severe COVID-19 [20]. According to these data, the combination therapy of azathioprine with anti-TNF biologic therapy is associated with a worse course of COVID-19 infection than monotherapy with this type of biologic therapy [20].

The immunogenicity of SARS-CoV-2 vaccines appears to be lowered in immunocompromised patients compared to the general population. In studies with transplant recipients, suboptimal immunogenicity with SARS-CoV-2 vaccination was evident [21, 22]. Prevalence of anti–SARS-CoV-2 antibodies at 4 weeks after the 2nd dose of vaccine in all transplant patients was present only in 34% of patients [21]. Compared to that, the effectiveness of vaccination was present in 92% of patients (85% fully responders, 8% partial responders) 4 weeks after the 2nd dose according to our response criteria.

Vaccination against COVID-19 infection is widely recommended to all adult non-pregnant patients with IBD regardless of used therapy despite the fact that patients with immunosuppressive or biological therapy could have lower vaccine efficacy [23–25]. The efficacy of the BNT162b2 vaccine (Pfizer-BioNTech SARS-CoV-2 vaccine) used in our study was proved in a large placebo-controlled phase III trial—95% efficacy in preventing symptomatic COVID-19 infection [26]. Subsequent studies have more or less confirmed this level of protection [27–29]. The pilot study evaluated the effect of vaccination with BNT162b2 in the context of confirmed COVID-19 cases from all participants in a two-month follow-up after vaccination [26]. SARS-CoV-2 antibody levels have not been evaluated in these studies and nowadays no routine post-vaccination testing for COVID-19 is recommended and its exact role remains unclear. In our study, the degree of immunogenicity of vaccination against SARS-CoV-2 in terms of antibody production was evaluated, and not the percentage of patients who underwent COVID-19 infection after vaccination. According to our data, a clear acceleration of SARS-CoV-2 antibody levels after the 2nd dose is evident. The geometric mean levels of SARS-CoV-2 antibodies in all three groups of patients increased significantly from 34.9–40.7 before 2nd dose to 500.1–676.5 4 weeks after 2nd dose. The level of antibodies guaranteeing protection has not been determined by available studies; in our study, it was determined empirically according to clinical experience with this infection. This differentiation of patients is certainly not exact, but it can help us select patients with a very poor antibody response to vaccination and recommend an early alternative procedure such as revaccination with another type of vaccine. For this reason, we consider routine testing of SARs-CoV-2 antibody levels after vaccination to be rational in high-risk patients.
Responders (SARS-CoV-2 antibodies IgG 500 U/ml and more) and partial responders (SARS-CoV-2 antibodies IgG 100–499 U/ml) after 1st dose and four weeks after the 2nd dose were in our study 32.2% and 92% of patients, respectively. The main effect and necessity of the 2nd dose of vaccination for SARS-CoV-2 is clear from our data. Only a small proportion of patients in our study did not reach an antibody response after the second SARS-COV-2 dose. These data are consistent with the results of the Kennedy et al. study, which was recently carried out on patients with IBD on biological therapy [30]. Based on this study, infliximab is associated with low immunogenicity after the 1st dose of the BNT162b2 and ChAdOx1 vaccines while on the other hand the 2nd dose of vaccine led to seroconversion in most patients. We have also demonstrated that doses of azathioprine more than 2mg/kg or intensified regime of biological therapy are not associated with lower representation of responders and partial responders after vaccination.

A combination therapy of biological and immunosuppressive therapy could lead to attenuated immunogenicity to both vaccines in infliximab-treated patients [30]. We directly compared the differences between the three groups of patients based on their therapy (biological therapy, immunosuppressive therapy with azathioprine and combination therapy of immunosuppressive therapy with azathioprine and biological therapy) and no statistically significant differences were proved in SARS-CoV-2 IgG antibody trends. To this date, no other study has directly compared the effect of these types of therapy on immunogenicity following SARS-CoV-2 vaccination.

In our group of patients, two basic types of local reaction after vaccination were observed: local erythema and/or local pain. On the day of administration, these local reactions were observed in approximately 60% of patients after both doses. The majority of these problems was present the day after vaccination—in 75.5% of patients after the 1st dose and in 65.3% of patients after the 2nd dose. This trend of maximum local reactions on the day following vaccination is in correlation with another study dealing with SARS-CoV-2 vaccine adverse events [31]. According to the data of the next study, after the 1st and 2nd doses of BNT162b2, local reactions were present on the day of application in about 30% and 40% of patients, respectively, and in the following day in 70% and 80% of patients, respectively [27]. These results correlate with our data. In our group of patients and in terms of local reactions, the 2nd dose of the vaccine was better tolerated, compared to the above-mentioned study.

A maximum of general adverse events was observed in our study on the day of administration and the following day after both doses of vaccine, in the following days there was a significant decrease of these problems. After the 1st and 2nd doses, a total of 41 and 42 adverse reactions were reported on day 0 and 34 and 59 adverse reactions on day 1, respectively. The most common general reactions were: fever, myalgia, arthralgia, cephalgia and fatigue. Gee et al. reported that fatigue, headache, and myalgia were present on day 0 after the 1st and 2nd doses in approximately 10, 10, and 5% and in 15, 10, and 5%, respectively, and on day 1 after the 1st and 2nd doses in approximately 25, 50, and 15% and in 55, 45, and 50% [31]. In comparison to our data, these adverse events were also present more often after the 2nd dose and with maximum on the day after vaccination, but not so often. Anaphylactic reactions following COVID-19 vaccines have been reported in 4.5 cases per million doses [31]. We reported no severe allergic reaction in terms of anaphylaxis.

Limitations of this study are:

1. Short-term study on relatively small number of patients.

2. Real effectiveness of vaccination against COVID-19 infection was not evaluated in our study. The immunogenicity of the vaccine and the production of antibodies against COVID-19 were measured.
3. The concentration of IgG against COVID-19 was measured up to the maximum limit of 1000 U / ml. This fact may affect the assessment of the median levels of IgG antibodies in our study groups in terms of underestimation of our results (not overestimation). However, it has no effect on the evaluation of COVID-19 vaccination responses.

**Conclusion**

SARS-CoV-2 vaccination should be recommended for all adult non-pregnant patients with CD or UC regardless of the therapy as soon as possible. Our study proved the efficacy of vaccination against COVID-19 in patients with IBD treated by immunosuppressive and/or biological therapy. No statistically significant differences of vaccine immunogenicity were proved between these groups of patients. We also proved the safety of SARS-CoV-2 vaccination, because adverse reactions following vaccination were only minor and of short duration in our study.

**Supporting information**

S1 Fig. Adverse events questionnaire. Questionnaire focused on the safety of the administered vaccine.

(DOCX)

S1 File. Source data of this study divided into four tables.

(XLSX)

**Author Contributions**

**Conceptualization:** Martin Wasserbauer, Stepan Hlava, Milan Trojanek, Tomas Milota, Jiri Drabek, Radan Keil.

**Data curation:** Martin Wasserbauer, Stepan Hlava, Milan Trojanek.

**Formal analysis:** Martin Wasserbauer, Stepan Hlava, Jan Stovicek, Petra Koptová, Andrea Cupkova, Barbora Kucerova.

**Investigation:** Stepan Hlava.

**Methodology:** Stepan Coufal.

**Supervision:** Radan Keil.

**Validation:** Stepan Coufal.

**Writing – original draft:** Martin Wasserbauer, Stepan Hlava, Tomas Milota, Jiri Drabek, Petra Koptová, Andrea Cupkova, Barbora Kucerova, Stepan Coufal.

**Writing – review & editing:** Jan Stovicek, Dita Pichlerová, Radan Keil.

**References**

1. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med. 2021 Jan; 174(1):69–79. https://doi.org/10.7326/ M20-5008 Epub 2020 Sep 17. PMID: 32941052; PMCID: PMC7505025.

2. Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med. 2020 Feb 27; 382(9):872–874. https://doi.org/10.1056/NEJMc2001272 PMID: 31991079
Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease

3. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020 Apr; 10(2):102–108. https://doi.org/10.1016/j.jpha.2020.03.001 Epub 2020 Mar 5. PMID: 32282863; PMCID: PMC7104082.

4. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May; 8(5):475–481. https://doi.org/10.1016/S2213-2600(20)30079-5 PMID: 32105632

5. Feldman M, Friedman L, Bramdt L, et al. Steisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management. 11th ed. Philadelphia (PA): Elsevier; 2021. p. 1868–1929.

6. Baumgart D. Crohn's disease and ulcerative colitis from epidemiology and immunobiology to a rational diagnostic and therapeutic approach. 1st ed. New York (NY): Springer; 2012. p. 3–74.

7. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491:119–24. https://doi.org/10.1038/nature11582 PMID: 23128233

8. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014 Jun; 8(6):443–68. https://doi.org/10.1016/j.crohns.2013.12.013 PMID: 24613021

9. Macaluso FS, Orlando A. COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data. Dig Liver Dis. 2020 Nov; 52(11):1222–1227. https://doi.org/10.1016/j.dld.2020.09.002 PMID: 32928672

10. Maconi G, Bosetti C, De Monti A, Boyapati RK, Shelton E, Piazza N, et al. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population. Dig Liver Dis. 2021 Mar; 53(3):263–270. https://doi.org/10.1016/j.dld.2020.12.013 PMID: 33483259

11. Brenner EJ, Ungaro RC, Geary RB, Kellogg H, Kossou-Hunt M, Lewis JD, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020 Aug; 159(2):481–491.e3 https://doi.org/10.1053/j.gastro.2020.05.032 PMID: 32425234

12. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct; 586(7830):516–527. https://doi.org/10.1038/s41586-020-2521-4 PMID: 32640463

13. Habas K, Ngarwuchu C, Shahzad F, Gopalan R, Haque M, Rahman S, et al. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev Anti Infect Ther. 2020 Dec; 18(12):1201–1211. https://doi.org/10.1080/14787210.2020.1797487 PMID: 32749914

14. Verity R, Okell LC, Dorrigati I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun; 20(6):669–677. https://doi.org/10.1016/S1473-3099(20)30243-7 PMID: 32240634

15. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May 26; 323(20):2052–2059. https://doi.org/10.1001/jama.2020.6775 PMID: 32320003

16. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug; 584(7821):430–436. https://doi.org/10.1038/s41586-020-2521-4 PMID: 32640463

17. Petritti CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chemyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22; 369:m1966. https://doi.org/10.1136/bmj.m1966 PMID: 32444366

18. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. 2020 Sep 10; 17(9):e1003321. https://doi.org/10.1371/journal.pmed.1003321 PMID: 32911500

19. Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020 Jul; 159(1):350–357. https://doi.org/10.1053/j.gastro.2020.04.012 PMID: 32283100

20. Ungaro RC, Brenner EJ, Geary RB, Kellogg H, Kossou-Hunt M, Lewis JD, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021 Apr; 70(4):725–732. https://doi.org/10.1136/gutjnl-2020-322539 PMID: 33082265

21. Marion O, Del Bello A, Abravanel F, Coupot C, Faguer S, Esposito L, et al. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. Ann Intern Med. 2021 Sep; 174(9):1336–1338. https://doi.org/10.7326/M21-1341 PMID: 34029487
22. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021 Jun 1; 325(21):2204–2206. https://doi.org/10.1001/jama.2021.7489 PMID: 33950155

23. Alexander JL, Moran GW, Gaya DR, Raine T, Hart A, Kennedy NA, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021 Mar; 6(3):218–224. https://doi.org/10.1016/S2468-1253(21)00024-8 PMID: 33508241

24. Siegel CA, Melmed GY, McGovern DP, Rai V, Krammer F, Rubin DT, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021 Apr; 70(4):635–640. https://doi.org/10.1016/S0017-5138(21)00024-8 PMID: 33508241

25. Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, et al. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep. 2021 Jul; 3(4):212–228. https://doi.org/10.1002/ygh2.473 PMID: 34539248

26. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31; 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577 PMID: 33301246

27. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021 May 15; 397(10287):1819–1829. https://doi.org/10.1016/S0140-6736(21)00947-8 PMID: 33964222

28. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021 May 8; 397(10286):1725–1735. https://doi.org/10.1016/S0140-6736(21)00947-8 PMID: 33964222

29. Benenson S, Oster Y, Cohen MJ, Nir-Paz R, BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers. N Engl J Med. 2021 May 6; 384(18):1775–1777. https://doi.org/10.1056/NEJMMc2101951 PMID: 33755373

30. Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021 Oct; 70(10):1884–1893. https://doi.org/10.1136/gutjnl-2021-324789 PMID: 33903149

31. Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First Month of COVID-19 Vaccine Safety Monitoring—United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021 Feb 26; 70(8):283–288. https://doi.org/10.15585/mmwr.mm7008e3 PMID: 33630816